| Gene Set | Leading Edge Genes |
|---|
| NETPATH TNF ALPHA PATHWAY UP | CSF3, CETN2, HBEGF, PSMA2, NFKBIA, GCH1, PSMA3, INHBA, CYC1, UGCG, CXCL10, YLPM1, HMGN2, ATP5O, NME2, SEMA3E, JUNB, S100A4, RYK, GGH, NFKB2, CCL2, PSMA5, ISGF3G, TMSB10, PPIA, CLIC4, TRAF1, CCL7, PSMB7, CCL5, PDCD5, RPL27A, IER3, S100A11, PSMD6, TRIM21, IFNB1, IL6, FBL, SEC61G, PTGS2, ZFP36, DYNLL1, EIF3S5, ATP5I, SEC23B, NDUFB8, CXCL2, SF3A3, SOD2, PSME1, EMP3, NFKB1, TNIP1, TGFBR3, TRAF3, ARMET, BCL3, SLC22A4, ATP5J, GBP2, POLR2H, CKS2, IL1B, PDE8A, ICAM1, EBP, LDLR, HDLBP, LPL, TNFRSF1B, RRS1, VEGFC, TSPAN3, RPA3, IL2RA, CSF2, DSCR2, IFIT2, PCLO, BIRC3, LTB, CD5, COX7A2, ADAM17, CXADR, ETS2, ACLY, CCNC, PSMB3, IFI27, SNRPD2, MRPL39, PLAUR |
| NETPATH IL 5 PATHWAY UP | CYP1A2, PLSCR1, HMGCR, PDE4B, NFKB2, CCL2, HBEGF, HIF1A, EGR1, PIM1, IL2RA, CD24, IER3, NFKB1, BIRC3, TRAF3, LTB, IL1A, NFIL3, LCP2, ACP5, IDI1, IL1B, CCL3, ZYX, ICAM1, CTSC, PSMB4 |
| NETPATH IL 1 PATHWAY UP | CSF3, HBEGF, PRG1, NFKBIA, SOD3, POLR2K, PSMA3, INHBA, CXCL2, SOD2, NFKB1, CKS2, CHI3L1, DCN, AK2, SERPINE1, IL1B, ICAM1, MYC, GTF2F1, LDHB, CCL2, CCL7, PIM2, MT2A, CSF2, CCL4, TTK, BIRC3, SULT4A1, IL6, PTGS2, ZFP36, PIP5K1A |
| MOOTHA VOXPHOS | ATP5I, ATP5C1, ATP5D, NDUFA5, NDUFB8, SURF2, NDUFB5, COX5B, CYC1, COX7B, ATP5O, UQCRB, ATP5J, COX7A2, COX6A1, NDUFAB1, COX6C, NDUFS3, SDHD |
| NETPATH KIT RECEPTOR PATHWAY UP | CCL22, NOL1, SNAI1, CCL2, EGR1, HRAS, CCL17, CYC1, CCL5, SOCS1, PIM1, CSF2, IER3, YWHAH, GDF15, JUNB, TPSAB1, IL6, ERCC1, RABGGTB, MYC, TNF |
| NETPATH IL 4 PATHWAY DOWN | NPAS2, GADD45B, CDKN1A, CCL2, LTB, LPL, GAS1, GBP2, NFKBIA, GEM, PTGS2, ICAM1, CXCL2, TNF, GZMA |
| NETPATH TNF ALPHA PATHWAY | PSMD7, NFKBIA, NFKBIZ, NFKB1, TNIP1, YWHAG, TRAF3, BCL3, CSNK2A2, KPNA6, POLR2H, TNFAIP3, TRAF6, CAV1, LRPPRC, KTN1, NFKB2, PFDN2, TNFRSF1B, HSP90AA1, PSMC3, TRAF1, PSMC1, PSMD1, MARK2, YWHAH, YWHAB, RPS6KB1, BIRC3, PSMD6, PSMD13, PSMD12, IQGAP2, KPNA3, HDAC2, FBL, TNF |
| NCI IL23PATHWAY | NFKB1, SOCS3, NFKBIA, IL1B, CCL2, MPO, TNF |
| NETPATH IL 3 PATHWAY UP | CCL2, CISH, SOCS3, CCL7, CCL3, IL1B, PIM1, CD86, MYC, CCL4, TNF |
| NETPATH IL 6 PATHWAY UP | GADD45B, PPARD, RETN, CEBPD, LDLR, JUNB, BCL3, CISH, HBEGF, SOCS3, PIM2, ZFP36, ID2, PIM1, TNF |
| NCI TNFPATHWAY | CAV1, NFKB1, BIRC3, TNFRSF1B, ADAM17, MAP4K2, TRAF1, TNF |
| CORUM HCF-1 COMPLEX | RBBP7, HDAC2, HSPA5, RBBP4, SAP30, HSP90AA1, HSPA4 |
| ST TUMOR NECROSIS FACTOR PATHWAY | NFKB1, NFKBIA, BIRC3, NFKB2, TNFRSF1B, TNF |
| SA MMP CYTOKINE CONNECTION | IL1B, TNFRSF1B, TNF |
| NCI ANTHRAXPATHWAY | CALM1, MAP2K2, IL1B, TNF |
| NETPATH IL 9 PATHWAY UP | CCL2, JUNB, BCL3, CISH, CDKN2D, SOCS3, CCL7, CCL3, PIM1, MYC |
| NETPATH IL 7 PATHWAY UP | RBBP4, TRAF3, CD19, CDKN2D, CD80, CCL3, CCL17, CXCL2, CD86, MYC, CCL4 |
| NCI APC C CDC20 MEDIATED DEGRADATION OF SECURIN | PSMC5, PSMD7, PSMA2, PSMA5, PSMB6, PSMC3, PSMD1, PSMC1, PSMB7, PSMC4, PSMA3, PSMA7, UBE2E1, PSME1, PSMB2, PSMA6, PSMD14, PSMA1, CDC20, PSMD10, PSMD6, PSMD12, PSMD13, PTTG1, PSMB3, CDC26, PSMC6, PSMB4 |
| NCI UBIQUITIN DEPENDENT DEGRADATION OF CYCLIN D1 | PSMC5, PSMD7, PSMA2, PSMA5, PSMB6, CDK4, PSMC3, PSMC1, PSMD1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD10, PSMD6, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI CDC20 PHOSPHO APC C MEDIATED DEGRADATION OF CYCLIN A | PSMC5, PSMD7, PSMA2, PSMA5, PSMB6, PSMC3, PSMD1, PSMC1, PSMB7, PSMC4, PSMA3, PSMA7, UBE2E1, PSME1, PSMB2, PSMA6, PSMD14, PSMA1, CDC20, PSMD10, PSMD6, PSMD12, PSMD13, PSMB3, CDC26, PSMC6, PSMB4 |
| NCI AURORA B PATHWAY | KIF20A, AURKB, CENPA, STMN1, SMC2, AURKA, CBX5, PSMA3, NCL, KIF23, PEBP1, RASA1, DES, CUL3, CDCA8, NPM1, BIRC5, MYLK |
| NETPATH IL 1 PATHWAY | NFKB1, NFKBIA, IL1RN, IL1B, PELI1 |
| NCI CHYLOMICRON MEDIATED LIPID TRANSPORT | SAR1B, LDLR, LPL, APOA5 |
| NCI HOST INTERACTIONS OF HIV FACTORS | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI SCF SKP2 MEDIATED DEGRADATION OF P27 P21 | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1 | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, CDC26, PSMC6, PSMB4 |
| CORUM PA700-20S-PA28 COMPLEX | PSMC5, PSMD7, PSMA2, PSMA5, PSMB6, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| CORUM MTA1 COMPLEX | RBBP7, HDAC2, RBBP4 |
| NCI VIF MEDIATED DEGRADATION OF APOBEC3G | PSMC5, PSMD7, PSMA2, PSMA5, TCEB1, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI DEGRADATION OF BETA CATENIN BY THE DESTRUCTION COMPLEX | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI REMOVAL OF LICENSING FACTORS FROM ORIGINS | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, ORC6L, PSMB7, MCM10, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD10, PSMD6, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI PROSTANOID HORMONES | PTGES3, PTGS2 |
| NCI FORMATION OF ATP BY CHEMIOSMOTIC COUPLING | ATP5O, ATP5I, ATP5C1, ATP5D, ATP5J |
| NCI UBIQUITIN MEDIATED DEGRADATION OF PHOSPHORYLATED CDC25A | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| CORUM F1F0-ATP SYNTHASE EC 3.6.3.14 MITOCHONDRIAL | ATP5O, ATP5I, ATP5C1, ATP5D, ATP5J |
| NCI ORC1 REMOVAL FROM CHROMATIN | PSMC5, PSMD7, PSMA2, PSMA5, PSMB6, PSMC3, PSMD1, PSMC1, ORC6L, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD10, PSMD6, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| CORUM PA700 COMPLEX | PSMC5, PSMD14, PSMD7, PSMD10, PSMD6, PSMD12, PSMD13, PSMC3, PSMD1, PSMC1, PSMC4, PSMC6 |
| NCI VPU MEDIATED DEGRADATION OF CD4 | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI AUTODEGRADATION OF CDH1 BY CDH1 APC C | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, CDC26, PSMC6, PSMB4 |
| NCI CDK MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6 | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX | PSMC5, PSMD7, PSMA2, PSMA5, PSMB6, PSMC3, PSMD1, PSMC1, ORC6L, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD10, PSMD6, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI REGULATION OF ACTIVATED PAK 2P34 BY PROTEASOME MEDIATED DEGRADATION1 | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI REGULATION OF ORNITHINE DECARBOXYLASE ODC | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI SWITCHING OF ORIGINS TO A POST REPLICATIVE STATE | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| NCI REGULATION OF ACTIVATED PAK 2P34 BY PROTEASOME MEDIATED DEGRADATION | PSMC5, PSMD7, PSMA2, PSMA5, PSMC3, PSMD1, PSMC1, PSMB7, PSMA3, PSMA7, PSME1, PSMD14, PSMA1, PSMA6, PSMD6, PSMD10, PSMD12, PSMD13, PSMB3, PSMC6, PSMB4 |
| GRAHAM NORMAL QUIESCENT VS NORMAL DIVIDING UP | |
| PUJANA BRCA1 PCC NETWORK | |
| SCIAN CELL CYCLE TARGETS OF TP53 AND TP73 DN | |
| BIOCARTA NFKB PATHWAY | |
| WEINMANN ADAPTATION TO HYPOXIA DN | |
| LEE EARLY T LYMPHOCYTE UP | |
| HORIUCHI WTAP TARGETS DN | |
| KEGG GRAFT VERSUS HOST DISEASE | |
| REACTOME PEPTIDE LIGAND BINDING RECEPTORS | |
| LINDSTEDT DENDRITIC CELL MATURATION B | |
| BIOCARTA IL1R PATHWAY | |
| CORUM C COMPLEX SPLICEOSOME | SYNCRIP, SNRPE, MAGOH, EFTUD2, THOC4, SF3A1, CRNKL1, SNRPD3, PRPF19, SF3B1, RBM8A, SNRPD2, U2AF1, SF3A3, SNRPA1 |
| BIOCARTA RELA PATHWAY | |
| NCI VIRAL MESSENGER RNA SYNTHESIS | GTF2F1, SNRPE, FUS, SFRS3, HNRPD, YBX1, SNRPD3, CCAR1, GTF2F2, NCBP2, POLR2K, HNRPH2, PCBP1, POLR2J, THOC4, SNRPD1, POLR2H, SNRPD2, U2AF1, POLR2C |
| RADAEVA RESPONSE TO IFNA1 UP | |
| AMIT EGF RESPONSE 40 HELA | |
| BOWIE RESPONSE TO EXTRACELLULAR MATRIX | |
| CORUM RNA POLYMERASE II RNAPII | POLR2H, GTF2F1, GTF2F2, POLR2C, POLR2J |
| REACTOME SCF SKP2 MEDIATED DEGRADATION OF P27 P21 | |
| THEILGAARD NEUTROPHIL AT SKIN WOUND UP | |
| REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 | |
| HINATA NFKB TARGETS KERATINOCYTE UP | |
| SOTIRIOU BREAST CANCER GRADE 1 VS 3 UP | |
| CORUM PA28GAMMA-20S PROTEASOME | PSMA1, PSMA6, PSMB7, PSMA3, PSMB3, PSMA2, PSMA7, PSMB4 |
| DORN ADENOVIRUS INFECTION 48HR DN | |
| REACTOME CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX | |
| REACTOME CHYLOMICRON MEDIATED LIPID TRANSPORT | |
| REACTOME SYNTHESIS OF DNA | |
| COULOUARN TEMPORAL TGFB1 SIGNATURE UP | |
| REACTOME TAT MEDIATED HIV1 ELONGATION ARREST AND RECOVERY | |
| SHEDDEN LUNG CANCER POOR SURVIVAL A6 | |
| BYSTRYKH SCP2 QTL | |
| REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA | |
| REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES | |
| SEITZ NEOPLASTIC TRANSFORMATION BY 8P DELETION UP | |
| GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS BLUE UP | |
| NCI ELONGATION ARREST AND RECOVERY | POLR2H, TCEB3, GTF2F1, GTF2F2, POLR2K, POLR2C, TCEB1, POLR2J |
| YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 11 | |
| STOSSI RESPONSE TO ESTRADIOL | |
| REACTOME APOPTOSIS | |
| MCLACHLAN DENTAL CARIES UP | |
| VANTVEER BREAST CANCER BRCA1 UP | |
| SHAFFER IRF4 TARGETS IN PLASMA CELL VS MATURE B LYMPHOCYTE | |
| CORUM CHROMOSOMAL PASSENGER COMPLEX CPC INCENP CDCA8 BIRC5 AURKB | CDCA8, AURKB, BIRC5 |
| ZHOU INFLAMMATORY RESPONSE LPS UP | |
| WINTER HYPOXIA UP | |
| GRADE COLON AND RECTAL CANCER UP | |
| FINETTI BREAST CANCER BASAL VS LUMINAL | |
| BERENJENO TRANSFORMED BY RHOA UP | |
| DORN ADENOVIRUS INFECTION 24HR DN | |
| PUIFFE INVASION INHIBITED BY ASCITES DN | |
| VERHAAK AML WITH NPM1 MUTATED UP | |
| NCI MRNA SPLICING MAJOR PATHWAY | SFRS9, FUS, MAGOH, SFRS3, SF3A1, YBX1, CCAR1, WDR57, NCBP2, POLR2K, PCBP1, SF3A3, POLR2J, PHF5A, THOC4, PCBP2, POLR2H, SF3B1, SNRPE, GTF2F1, HNRPD, SNRPD3, GTF2F2, HNRPH2, SNRPA1, NUDT21, PABPN1, EFTUD2, SNRPD1, DHX9, SF3B2, RBM8A, U2AF1, SNRPD2, POLR2C, SFRS11 |
| REACTOME G1 S TRANSITION | |
| FOURNIER ACINAR DEVELOPMENT LATE 2 | |
| CORUM SPLICEOSOME | SNRPE, MAGOH, SFRS3, SF1, SF3A1, LSM7, SNRPD3, SFRS6, PRPF19, NCBP2, BUD31, SF3A3, SNRPA1, NUDT21, DHX15, RBM17, EFTUD2, THOC4, SFRS2, CRNKL1, DHX9, THOC7, WTAP, PRPF4B, SNRPD2, RBM8A, U2AF1, DHX16, SFRS11, LSM2 |
| TIAN TNF SIGNALING VIA NFKB | |
| ZHANG PROLIFERATING VS QUIESCENT | |
| HUMMEL BURKITTS LYMPHOMA DN | |
| LY AGING PREMATURE DN | |
| NCI PAUSING AND RECOVERY OF HIV 1 ELONGATION | POLR2H, TCEB3, GTF2F1, GTF2F2, POLR2K, POLR2C, TCEB1, POLR2J |
| NCI TAT MEDIATED HIV 1 ELONGATION ARREST AND RECOVERY | POLR2H, TCEB3, GTF2F1, GTF2F2, POLR2K, POLR2C, TCEB1, POLR2J |
| SUH COEXPRESSED WITH ID1 AND ID2 UP | |
| REACTOME MITOTIC M M G1 PHASES | |
| REACTOME FORMATION AND MATURATION OF MRNA TRANSCRIPT | |
| SCHLOSSER MYC TARGETS AND SERUM RESPONSE DN | |
| NCI MRNA 3 END PROCESSING | SFRS9, MAGOH, SFRS3, THOC4, NCBP2, U2AF1, PCF11, RBM8A, SFRS11, NUDT21, PABPN1 |
| NCI MRNA SPLICING MINOR PATHWAY | GTF2F1, SNRPE, EFTUD2, SNRPD1, SNRPD3, POLR2H, WDR57, GTF2F2, POLR2K, NCBP2, SNRPD2, POLR2C, POLR2J |
| BHATTACHARYA EMBRYONIC STEM CELL | |
| REACTOME CELL CYCLE CHECKPOINTS | |
| RHODES UNDIFFERENTIATED CANCER | |
| CORUM CHROMOSOMAL PASSENGER COMPLEX CPC CDCA8 AURKB BIRC5 | |
| REACTOME RNA POLYMERASE II TRANSCRIPTION | |
| NAKAYAMA SOFT TISSUE TUMORS PCA2 DN | |
| ROYLANCE BREAST CANCER 16Q COPY NUMBER UP | |
| TARTE PLASMA CELL VS PLASMABLAST DN | |
| SESTO RESPONSE TO UV C1 | |
| CROONQUIST STROMAL STIMULATION UP | |
| REACTOME MRNA SPLICING | |
| NCI FORMATION OF THE HIV 1 EARLY ELONGATION COMPLEX | POLR2H, GTF2F1, GTF2F2, NCBP2, POLR2K, POLR2C, POLR2J |
| SIMBULAN UV RESPONSE NORMAL UP | |
| BIOCARTA CDMAC PATHWAY | |
| REACTOME ELONGATION AND PROCESSING OF CAPPED TRANSCRIPTS | |
| CORUM PA28-20S PROTEASOME | PSMA1, PSMA6, PSMA2, PSMA5, PSMB6, PSMB7, PSMA3, PSMB3, PSMA7, PSMB4, PSME1 |
| DORN ADENOVIRUS INFECTION 12HR UP | |
| NCI MRNA CAPPING | POLR2H, GTF2F1, GTF2F2, NCBP2, POLR2K, POLR2C, POLR2J |
| BIOCARTA SODD PATHWAY | |
| KEGG TERPENOID BACKBONE BIOSYNTHESIS | |
| BUDHU LIVER CANCER METASTASIS DN | |
| GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS BLACK UP | |
| DER IFN BETA RESPONSE UP | |
| REACTOME FORMATION OF ATP BY CHEMIOSMOTIC COUPLING | |
| DIRMEIER LMP1 RESPONSE LATE UP | |
| CAIRO HEPATOBLASTOMA CLASSES UP | |
| BASSO CD40 SIGNALING UP | |
| KORKOLA YOLK SAC TUMOR | |
| MARZEC IL2 SIGNALING UP | |
| NAGASHIMA NRG1 SIGNALING UP | |
| BIOCARTA PPARA PATHWAY | |
| PENG GLUTAMINE DEPRIVATION DN | |
| NCI HIV 1 TRANSCRIPTION ELONGATION | POLR2H, GTF2F1, GTF2F2, NCBP2, POLR2K, POLR2C, POLR2J |
| REACTOME DNA REPLICATION PRE INITIATION | |
| NCI PAUSING AND RECOVERY OF TAT MEDIATED HIV 1 ELONGATION | POLR2H, TCEB3, GTF2F1, GTF2F2, POLR2K, POLR2C, TCEB1, POLR2J |
| MAHADEVAN RESPONSE TO MP470 UP | |
| KEGG RIG I LIKE RECEPTOR SIGNALING PATHWAY | |
| BIOCARTA TID PATHWAY | |
| REACTOME REGULATION OF APC ACTIVATORS BETWEEN G1 S AND EARLY ANAPHASE | |
| REACTOME MRNA 3 END PROCESSING | |
| REACTOME VIF MEDIATED DEGRADATION OF APOBEC3G | |
| ZHANG ANTIVIRAL RESPONSE TO RIBAVIRIN DN | |
| CHEN HOXA5 TARGETS 9HR UP | |
| NCI ELONGATION OF INTRON CONTAINING TRANSCRIPTS AND CO TRANSCRIPTIONAL MRNA SPLICING | GTF2F1, HNRPD, POLR2H, GTF2F2, POLR2K, NCBP2, HNRPH2, POLR2C, PCBP1, POLR2J |
| SEKI INFLAMMATORY RESPONSE LPS UP | |
| GRAHAM CML QUIESCENT VS CML DIVIDING UP | |
| SENESE HDAC2 TARGETS DN | |
| MOSERLE IFNA RESPONSE | |
| FOSTER INFLAMMATORY RESPONSE LPS UP | |
| REACTOME MRNA SPLICING MINOR PATHWAY | |
| CORUM 20S PROTEASOME | PSMA1, PSMA6, PSMB7, PSMA3, PSMB3, PSMA2, PSMA7, PSMB4 |
| REACTOME SIGNALING BY WNT | |
| CORUM 26S PROTEASOME | PSMA1, PSMA6, PSMC5, PSMA2, PSMD13, PSMC3, PSMC1, PSMB7, PSMA3, PSMB3, PSMA7, PSMC6, PSMB4 |
| YU MYC TARGETS UP | |
| KIM WT1 TARGETS UP | |
| PEPPER CHRONIC LYMPHOCYTIC LEUKEMIA UP | |
| REACTOME CYTOCHROME P450 ARRANGED BY SUBSTRATE TYPE | |
| REACTOME ORC1 REMOVAL FROM CHROMATIN | |
| REACTOME AUTODEGRADATION OF CDH1 BY CDH1 APC | |
| ONDER CDH1 TARGETS 1 DN | |
| KEGG CYTOSOLIC DNA SENSING PATHWAY | |
| WOTTON RUNX TARGETS DN | |
| HESS TARGETS OF HOXA9 AND MEIS1 DN | |
| FINETTI BREAST CANCER KINOME RED | |
| WONG EMBRYONIC STEM CELL CORE | |
| RHODES CANCER META SIGNATURE | |
| VANTVEER BREAST CANCER METASTASIS DN | |
| REACTOME M G1 TRANSITION | |
| OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL DN | |
| BIOCARTA HIF PATHWAY | |
| NCI PAUSING AND RECOVERY OF ELONGATION | POLR2H, TCEB3, GTF2F1, GTF2F2, POLR2K, POLR2C, TCEB1, POLR2J |
| BIOCARTA PML PATHWAY | |
| GRAHAM CML DIVIDING VS NORMAL QUIESCENT UP | |
| LI WILMS TUMOR VS FETAL KIDNEY 1 DN | |
| PAL PRMT5 TARGETS UP | |
| CHANG CORE SERUM RESPONSE UP | |
| ZHU CMV 24 HR UP | |
| ICHIBA GRAFT VERSUS HOST DISEASE D7 UP | |
| OUELLET OVARIAN CANCER INVASIVE VS LMP UP | |
| LY AGING OLD DN | |
| LINDSTEDT DENDRITIC CELL MATURATION A | |
| KEGG RNA POLYMERASE | |
| KEGG SPLICEOSOME | |
| NCI FORMATION OF THE EARLY ELONGATION COMPLEX | POLR2H, GTF2F1, GTF2F2, NCBP2, POLR2K, POLR2C, POLR2J |
| REACTOME CHOLESTEROL BIOSYNTHESIS | |
| LE EGR2 TARGETS UP | |
| PUJANA CHEK2 PCC NETWORK | |
| KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY | |
| PENG LEUCINE DEPRIVATION DN | |
| BIOCARTA PROTEASOME PATHWAY | |
| DAVICIONI PAX FOXO1 SIGNATURE IN ARMS DN | |
| DUTTA APOPTOSIS VIA NFKB | |
| CORUM 12S U11 SNRNP | SNRPD3, SNRPE, SNRPD2, YBX1 |
| DIRMEIER LMP1 RESPONSE EARLY | |
| DER IFN GAMMA RESPONSE UP | |
| KEGG BASAL TRANSCRIPTION FACTORS | |
| BENNETT SYSTEMIC LUPUS ERYTHEMATOSUS | |
| BIOCARTA FREE PATHWAY | |
| ZHOU INFLAMMATORY RESPONSE LIVE UP | |
| SMID BREAST CANCER RELAPSE IN BRAIN UP | |
| ONDER CDH1 TARGETS 3 DN | |
| CORUM 17S U2 SNRNP | SNRPE, RBM17, SF3A1, SNRPD3, SF3B2, SF3B1, U2AF1, SNRPD2, SF3A3, SNRPA1, DHX15, PHF5A |
| BIOCARTA ERYTH PATHWAY | |
| DAZARD RESPONSE TO UV NHEK UP | |
| MORI IMMATURE B LYMPHOCYTE DN | |
| CORUM 18S U11/U12 SNRNP | |
| YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 13 | |
| FOSTER INFLAMMATORY RESPONSE LPS DN | |
| GAURNIER PSMD4 TARGETS | |
| REACTOME P53 INDEPENDENT DNA DAMAGE RESPONSE | |
| BOQUEST STEM CELL CULTURED VS FRESH DN | |
| AMIT SERUM RESPONSE 120 MCF10A | |
| NCI PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA | GTF2F1, HNRPD, POLR2H, GTF2F2, POLR2K, NCBP2, HNRPH2, POLR2C, PCBP1, POLR2J |
| REACTOME REGULATION OF ORNITHINE DECARBOXYLASE | |
| LEE LIVER CANCER MYC E2F1 UP | |
| SESTO RESPONSE TO UV C3 | |
| DAZARD UV RESPONSE CLUSTER G1 | |
| MIDORIKAWA AMPLIFIED IN LIVER CANCER | |
| GEISS RESPONSE TO DSRNA UP | |
| SATO SILENCED BY METHYLATION IN PANCREATIC CANCER 1 | |
| NCI CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION | SFRS9, MAGOH, SFRS3, THOC4, NCBP2, U2AF1, PCF11, RBM8A, SFRS11, NUDT21, PABPN1 |
| WEI MYCN TARGETS WITH E BOX | |
| ZHOU INFLAMMATORY RESPONSE FIMA UP | |
| MORI LARGE PRE BII LYMPHOCYTE UP | |
| ROSTY CERVICAL CANCER PROLIFERATION CLUSTER | |
| ZHU CMV ALL UP | |
| KEGG SYSTEMIC LUPUS ERYTHEMATOSUS | |
| VECCHI GASTRIC CANCER EARLY UP | |
| KEGG PROTEASOME | |
| LEE LIVER CANCER HEPATOBLAST | |
| NAGASHIMA EGF SIGNALING UP | |
| AMIT EGF RESPONSE 60 MCF10A | |
| BENPORATH PROLIFERATION | |
| KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION | |
| OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL UP | |
| NELSON RESPONSE TO ANDROGEN UP | |
| WHITEFORD PEDIATRIC CANCER MARKERS | |
| BIOCARTA EPONFKB PATHWAY | |
| SHEPARD BMYB TARGETS | |
| DORN ADENOVIRUS INFECTION 32HR DN | |
| ZHAN MULTIPLE MYELOMA PR UP | |
| REACTOME ABORTIVE ELONGATION OF HIV1 TRANSCRIPT IN THE ABSENCE OF TAT | |
| NCI HIV 1 ELONGATION ARREST AND RECOVERY | POLR2H, TCEB3, GTF2F1, GTF2F2, POLR2K, POLR2C, TCEB1, POLR2J |
| REACTOME PHASE 1 FUNCTIONALIZATION OF COMPOUNDS | |
| MARKEY RB1 ACUTE LOF DN | |
| SHAFFER IRF4 TARGETS IN MYELOMA VS MATURE B LYMPHOCYTE | |
| DAVICIONI TARGETS OF PAX FOXO1 FUSIONS DN | |
| GAUTSCHI SRC SIGNALING | |
| TAKEDA TARGETS OF NUP98 HOXA9 FUSION 3D UP | |
| HARRIS HYPOXIA | |
| REACTOME VIRAL MESSENGER RNA SYNTHESIS | |
| SOUCEK MYC TARGETS | |
| TAKEDA TARGETS OF NUP98 HOXA9 FUSION 6HR DN | |
| BILBAN B CLL LPL DN | |
| GOLDRATH ANTIGEN RESPONSE | |
| REACTOME CDC20 PHOSPHO APC MEDIATED DEGRADATION OF CYCLIN A | |
| DAUER STAT3 TARGETS UP | |
| LIANG SILENCED BY METHYLATION 2 | |
| ZUCCHI METASTASIS UP | |
| AMIT EGF RESPONSE 60 HELA | |
| PELLICCIOTTA HDAC IN ANTIGEN PRESENTATION DN | |
| DAZARD UV RESPONSE CLUSTER G2 | |
| MARKS HDAC TARGETS DN | |
| WINNEPENNINCKX MELANOMA METASTASIS UP | |
| NCI CD40 PATHWAY | |
| SCHUHMACHER MYC TARGETS UP | |
| WALLACE PROSTATE CANCER UP | |
| MCLACHLAN DENTAL CARIES DN | |
| KEGG ALLOGRAFT REJECTION | |
| AMIT SERUM RESPONSE 40 MCF10A | |
| LEE LIVER CANCER SURVIVAL DN | |
| CORUM 39S RIBOSOMAL SUBUNIT MITOCHONDRIAL | MRPL9, MRPL50, MRPL54, MRPL17, MRPL35, MRPL27, MRPL52, MRPL40, MRPL16, MRPL39, MRPL13, MRPL21, MRPL48, MRPL14, MRPL20 |
| BROWNE HCMV INFECTION 4HR UP | |
| ZHANG RESPONSE TO IKK INHIBITOR AND TNF UP | |
| HU ANGIOGENESIS DN | |
| NCI ABORTIVE ELONGATION OF HIV 1 TRANSCRIPT IN THE ABSENCE OF TAT | POLR2H, GTF2F1, GTF2F2, POLR2K, NCBP2, POLR2C, POLR2J |
| SANA TNF SIGNALING UP | |
| PENG RAPAMYCIN RESPONSE DN | |
| REACTOME STABILIZATION OF P53 | |
| GRAHAM CML QUIESCENT VS NORMAL QUIESCENT UP | |
| HAHTOLA MYCOSIS FUNGOIDES CD4 UP | |
| WEST ADRENOCORTICAL TUMOR UP | |
| SATO SILENCED BY METHYLATION IN PANCREATIC CANCER 2 | |
| SHAFFER IRF4 TARGETS IN ACTIVATED B LYMPHOCYTE | |
| FERREIRA EWINGS SARCOMA UNSTABLE VS STABLE UP | |
| UZONYI RESPONSE TO LEUKOTRIENE AND THROMBIN | |
| CORUM 55S RIBOSOME MITOCHONDRIAL | MRPL9, MRPS25, MRPS7, MRPL54, MRPL17, MRPL35, MRPS33, MRPL52, MRPL40, MRPS15, MRPL20, MRPS22, MRPS5, MRPL50, MRPL27, MRPS36, MRPL16, MRPL39, MRPL13, MRPL21, MRPS14, MRPL48, MRPL14 |
| REACTOME S PHASE | |
| CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS UP | |
| CHANG CYCLING GENES | |
| NETPATH T CELL RECEPTOR PATHWAY UP | |
| BOYAULT LIVER CANCER SUBCLASS G3 UP | |
| FARMER BREAST CANCER CLUSTER 2 | |
| NETPATH IL 2 PATHWAY UP | |
| CROONQUIST NRAS VS STROMAL STIMULATION DN | |
| GRAHAM CML QUIESCENT VS NORMAL DIVIDING UP | |
| GOUYER TATI TARGETS UP | |
| FUNG IL2 TARGETS WITH STAT5 BINDING SITES T1 | |
| RICKMAN HEAD AND NECK CANCER E | |
| REACTOME CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION | |